Vericel Corporation (NASDAQ:VCEL) shares saw unusually-strong trading volume on Tuesday . Approximately 1,033,493 shares were traded during trading, an increase of 105% from the previous session’s volume of 503,396 shares.The stock last traded at $4.30 and had previously closed at $3.85.

A number of research analysts have weighed in on VCEL shares. BTIG Research set a $6.00 price target on shares of Vericel Corporation and gave the company a “buy” rating in a research report on Monday, October 2nd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $7.00 price target on shares of Vericel Corporation in a research report on Thursday, August 10th.

The company has a debt-to-equity ratio of 0.44, a current ratio of 2.50 and a quick ratio of 2.22.

Vericel Corporation (NASDAQ:VCEL) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Vericel Corporation had a negative net margin of 45.11% and a negative return on equity of 265.45%. The business had revenue of $14.26 million for the quarter. equities analysts anticipate that Vericel Corporation will post -0.6 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of VCEL. Archon Capital Management LLC acquired a new position in shares of Vericel Corporation during the second quarter worth $4,412,000. First Washington CORP acquired a new stake in Vericel Corporation in the second quarter valued at $2,230,000. Perkins Capital Management Inc. raised its holdings in Vericel Corporation by 118.4% in the third quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock valued at $3,376,000 after acquiring an additional 305,000 shares in the last quarter. EAM Investors LLC acquired a new stake in Vericel Corporation in the third quarter valued at $943,000. Finally, Vanguard Group Inc. raised its holdings in Vericel Corporation by 7.9% in the second quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock valued at $4,002,000 after acquiring an additional 88,645 shares in the last quarter. 37.93% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Vericel Corporation (VCEL) Sees Strong Trading Volume” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/vericel-corporation-vcel-sees-strong-trading-volume/1718548.html.

About Vericel Corporation

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.